0.30
+0.0029(+0.97%)
Currency In USD
| Previous Close | 0.3 |
| Open | 0.31 |
| Day High | 0.32 |
| Day Low | 0.3 |
| 52-Week High | 1.35 |
| 52-Week Low | 0.24 |
| Volume | 239,274 |
| Average Volume | 913,390 |
| Market Cap | 5.1M |
| PE | -0.82 |
| EPS | -0.37 |
| Moving Average 50 Days | 0.33 |
| Moving Average 200 Days | 0.46 |
| Change | 0 |
If you invested $1000 in Biomerica, Inc. (BMRA) 10 years ago, it would be worth $336.67 as of January 03, 2025 at a share price of $0.303. Whereas If you bought $1000 worth of Biomerica, Inc. (BMRA) shares 5 years ago, it would be worth $107.83 as of January 03, 2025 at a share price of $0.303.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
GlobeNewswire Inc.
Nov 21, 2024 1:19 PM GMT
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries withi
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements
GlobeNewswire Inc.
Nov 07, 2024 2:09 PM GMT
IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
GlobeNewswire Inc.
Oct 30, 2024 12:19 PM GMT
Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s officeWith a simple, at-home finger-prick blood sample, patients can receive a personalized